Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%

VERACYTE, INC.

2025-Q1 EPS reported $0.09 revenue$114,473,000

Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).
Decipher revenue $66.6M (+33%); Afirma revenue $38.3M (+6%); Decipher volume ~22,600 (+37%).
Net income $7.0M (6.2% of revenue); adjusted EBITDA $24.7M (21.6% of revenue).
Launched limited access to Decipher for metastatic prostate cancer, expanding addressable population.
Cash and short-term investments $287.4M; generated $5.4M cash from ops.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.